Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

Market Cap	26.24B -34.1%
Revenue (ttm)	5.99B -2.2%
Net Income	972.56M -34.1%
EPS	0.49 -34.1%
Shares Out	1.98B
PE Ratio	27.28
Forward PE	28.25
Dividend	0.20 (1.49%)
Ex-Dividend Date	Sep 25, 2025

Volume	7,901,741
Open	13.31
Previous Close	13.39
Day's Range	13.16 - 13.43
52-Week Range	13.15 - 22.08
Beta	0.19
Analysts	Buy
Price Target	19.50 (+46.95%)
Earnings Date	Apr 30, 2026

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 5,205
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2025, SHA:600161's revenue was 6.17 billion, an increase of 2.26% compared to the previous year's 6.03 billion. Earnings were 1.09 billion, a decrease of -29.59%.